This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.
Study Type
OBSERVATIONAL
Enrollment
2,795
Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only
AASIS- is a scale assessing the severity of AA-related symptoms on daily functioning. Each item scored on a 0-10 Likert scale, where 0 = not present and 10 = as bad as you can imagine Higher total score = greater impact
Time frame: Up to Day 1
Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only
SALT is a Tool developed to quantify AA-related hair loss Total score of 0-100, with 0 = no hair loss, and 100 = complete hair loss
Time frame: Up to Day 1
Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only
F-VASI is a quantitative scoring tool used to evaluate the extent and severity of facial vitiligo calculated by multiplying the degree of skin depigmentation of the face
Time frame: Up to Day 1
Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only
VitiQoL is a 16-item instrument assessing impact of vitiligo on QoL. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"
Time frame: Up to Day 1
Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only
CDLQI is a10-question index measuring health-related quality of life (HRQoL) over the last 7 days for patients suffering from a skin disease. The DLQI is used in participants aged 16 and over and the CDLQI has been validated from the ages of 4 to 16 years. Each item scored on a 4-point Likert scale, where 0 = not at all/not relevant/question unanswered and 3 = very much. Maximum total score = 30 (highest impact on QoL).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital Britanico de Buenos Aires /ID# 278940
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
RECRUITINGBuenos Aires Skin /ID# 277637
Buenos Aires, Argentina
RECRUITINGCentro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 277634
Buenos Aires, Argentina
RECRUITINGHospital Italiano de Buenos Aires /ID# 277636
Buenos Aires, Argentina
RECRUITINGInstituto de Neumonología y Dermatología /ID# 277635
Buenos Aires, Argentina
RECRUITINGDermatology Research Institute - Blackfoot Trail /ID# 276548
Calgary, Alberta, Canada
RECRUITINGRejuvenation Dermatology - Edmonton Downtown /ID# 276593
Edmonton, Alberta, Canada
RECRUITINGAlberta Dermatology Consultants /ID# 277187
Edmonton, Alberta, Canada
RECRUITINGBrunswick Dermatology Center /ID# 276546
Fredericton, New Brunswick, Canada
RECRUITINGSimcoderm Medical And Surgical Dermatology Centre /ID# 276838
Barrie, Ontario, Canada
RECRUITING...and 106 more locations
Time frame: Up to Day 1
Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only
The IHS4 score is calculated as follows: number of nodules (multiplied by 1) + number of abscesses (multiplied by 2) + number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.
Time frame: Up to Day 1